GNX80 is developed by SK Chemicals Co., Ltd..

What development phase is GNX80 in?

GNX80 is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

GNX80

SK Chemicals Co., Ltd. · FDA-approved active Small molecule Quality 4/100

GNX80, a small molecule drug marketed by SK Chemicals Co., Ltd., holds an established position in its therapeutic area despite the unknown mechanism of action. The drug's key strength lies in its current market presence, which is protected by a key composition patent expiring in 2028. The primary risk to GNX80 is the uncertainty surrounding its mechanism of action, which may impact future regulatory and market acceptance.

At a glance

Generic name	GNX80
Also known as	Test
Sponsor	SK Chemicals Co., Ltd.
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Clinical Trial for GNX80 in Intermittent Claudication (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GNX80 CI brief — competitive landscape report
GNX80 updates RSS · CI watch RSS
SK Chemicals Co., Ltd. portfolio CI